AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19669786 — intervention group
Group type: COMPARATOR
Intervention: 5 min forearm occlusion
Number of subjects: 14
Study 16687511 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) group
Number of subjects: 0
Study 16687511 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic dementia (SD) group
Number of subjects: 0
Study 15219644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (open label treatment for 6 weeks)
Number of subjects: 20
Study 15219644 — intervention group
Group type: COMPARATOR
Intervention: Metyrapone challenge (evening)
Number of subjects: 20
Study 11705814 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin cerivastatin (HMG‐CoA reductase inhibitor)
Number of subjects: 30
Study 11705814 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 30
Study 11705814 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate hypercholesterolemia
Number of subjects: 30
Study 9342964 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily nitrate therapy
Number of subjects: 1212
Study 9342964 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose nitrate therapy
Number of subjects: 1212
Study 8508698 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium chloride
Number of subjects: 14
Study 8508698 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 14
Study 3472492 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic applied to the anterior nares
Number of subjects: 18
Study 3472492 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin alone (Control)
Number of subjects: 18
Study 29165837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse width of 30 µs
Number of subjects: 15
Study 29165837 — intervention group
Group type: COMPARATOR
Intervention: Pulse width of 60 µs
Number of subjects: 15
Study 27930448 — intervention group
Group type: EXPERIMENTAL
Intervention: Kettlebell swings (KBSs) with warm-up followed by 8 consecutive 20-second rounds of KBS with 10-second rest periods
Number of subjects: 60
Study 27930448 — intervention group
Group type: COMPARATOR
Intervention: Warm-up alone (Control group)
Number of subjects: 60
Study 26657793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic Rehabilitation (PR)
Number of subjects: 296
Study 26657793 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Listening (SL)
Number of subjects: 296
Study 26657793 — intervention group
Group type: COMPARATOR
Intervention: General Practitioner Treatment as Usual (Control)
Number of subjects: 296
Study 23279972 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent knowledge-translation intervention (clinician education, paper-based VTE risk assessment algorithm, printed physicians' orders, audit and feedback sessions)
Number of subjects: 2611
Study 23279972 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no active strategies for thromboprophylaxis)
Number of subjects: 2611
Study 21907756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk (2.5 ppm, 5 ppm, 7.5 ppm, 10 ppm, 15 ppm, 20 ppm, 250 ppm) with 25 ml/section and 50 ml/section
Number of subjects: 0
Study 21907756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk (2.5 ppm)
Number of subjects: 0
Study 21907756 — intervention group
Group type: COMPARATOR
Intervention: De-ionized water and plain milk
Number of subjects: 0
Study 21907756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk (various concentrations)
Number of subjects: 0
Study 18676140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bec2 (2.5mg)/BCG vaccine arm (VA)
Number of subjects: 515
Study 18676140 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 515
Study 16014329 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 5 mg
Number of subjects: 0
Study 16014329 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 0
Study 16014329 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 0
Study 16014329 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 0
Study 16014329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12612296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 25‐1553 (600 microg)
Number of subjects: 24
Study 12612296 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (4.5 microg)
Number of subjects: 24
Study 12612296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10853852 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d.
Number of subjects: 144
Study 10853852 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d. plus ipratropium 40 microg q.i.d.
Number of subjects: 144
Study 10853852 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d. and Salmeterol 50 microg b.i.d. plus ipratropium 40 microg q.i.d.
Number of subjects: 144
Study 10853852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 9534284 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program based on anaerobic threshold
Number of subjects: 44
Study 9534284 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 8189744 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication at .10 breath alcohol concentration
Number of subjects: 48
Study 8189744 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication at .05 breath alcohol concentration
Number of subjects: 48
Study 3059851 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 15
Study 3059851 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 15
Study 3059851 — intervention group
Group type: COMPARATOR
Intervention: Both anaesthetics
Number of subjects: 15
Study 31600930 — intervention group
Group type: EXPERIMENTAL
Intervention: Prudent diet
Number of subjects: 42
Study 31600930 — intervention group
Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 42
Study 28251346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventriculoperitoneal (VP) shunt surgery
Number of subjects: 0
Study 28251346 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumboperitoneal (LP) shunt surgery
Number of subjects: 0
Study 28251346 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt surgery for iNPH
Number of subjects: 0
Study 25733175 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents with stent length < 20 mm
Number of subjects: 112
Study 25733175 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents with stent length ≥ 20 mm
Number of subjects: 112
Study 25733175 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant post-dilatation
Number of subjects: 112
Study 25733175 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall stent deployment
Number of subjects: 112
Study 23182874 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 0
Study 23182874 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study 21194775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0
Study 21194775 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nateglinide and GLP‐1 derivatives
Number of subjects: 0
Study 18438905 — intervention group
Group type: EXPERIMENTAL
Intervention: Durometer measurements of skin hardness
Number of subjects: 43
Study 18438905 — intervention group
Group type: COMPARATOR
Intervention: Modified Rodnan skin score (MRSS)
Number of subjects: 43
Study 16495425 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR only (N = 2,426)
Number of subjects: 6182
Study 16495425 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR+AED (N = 3,756)
Number of subjects: 6182
Study 16495425 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing and retraining for CPR skills
Number of subjects: 6182
Study 16495425 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing and retraining for CPR+AED skills
Number of subjects: 6182
Study 14550939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10‐20 mg alone
Number of subjects: 5
Study 14550939 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol patch 0.1‐0.2 mg alone
Number of subjects: 5
Study 14550939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10‐20 mg and estradiol patch 0.1‐0.2 mg (combination treatment)
Number of subjects: 5
Study 12842676 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear corneal incision (AcrySof IOL)
Number of subjects: 123
Study 12842676 — intervention group
Group type: COMPARATOR
Intervention: Scleral incision (PMMA IOL)
Number of subjects: 123
Study 12842676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study 10441772 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical treatment for osteoporosis
Number of subjects: 0
Study 10441772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomized response based on predefined threshold
Number of subjects: 0
Study 8537805 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol 4 mg by mouth three times daily for 7 days
Number of subjects: 104
Study 8537805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 1794242 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin tablets
Number of subjects: 436
Study 1794242 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin capsules
Number of subjects: 436
Study 1794242 — intervention group
Group type: COMPARATOR
Intervention: Enoxacin
Number of subjects: 436
Study 1794242 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 436
Study 10263521 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language prenatal health-education classes covering newborn care, labor and delivery, family planning, and dental health care.
Number of subjects: 0
Study 10263521 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched group of women who did not attend the classes).
Number of subjects: 0
Study 2427144 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (50 pmol)
Number of subjects: 6
Study 2427144 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (H1-receptor antagonist)
Number of subjects: 6
Study 31340321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar oblique-pulling manipulation in combination with sling-exercise-therapy training
Number of subjects: 60
Study 31340321 — intervention group
Group type: COMPARATOR
Intervention: Sling-exercise-therapy training
Number of subjects: 60
Study 29273044 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (3 times/week for 16 weeks from 16-20 to 32-36 weeks' gestation)
Number of subjects: 639
Study 26337246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (TXA) administered as a bolus dose of 15 mg/kg 10 minutes before tourniquet inflation and an infusion of 10 mg/kg/h for 3 hours post-operation
Number of subjects: 105
Study 26337246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (TXA)
Number of subjects: 105
Study 26337246 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 105
Study 23222500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer cases (121,293 persons)
Number of subjects: 121293
Study 23222500 — intervention group
Group type: COMPARATOR
Intervention: Matched noncancer control groups (522,839 persons)
Number of subjects: 121293
Study 21644186 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief strategic therapy
Number of subjects: 120
Study 21644186 — intervention group
Group type: COMPARATOR
Intervention: Minimal supportive therapy
Number of subjects: 120
Study 18262853 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 76
Study 18262853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 16628330 — intervention group
Group type: EXPERIMENTAL
Intervention: Viabahn covered stents
Number of subjects: 0
Study 16628330 — intervention group
Group type: COMPARATOR
Intervention: Bare nitinol stents
Number of subjects: 0
Study 15280841 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 U of BTX‐A
Number of subjects: 119
Study 15280841 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U of BTX‐A
Number of subjects: 119
Study 15280841 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 U of BTX‐A
Number of subjects: 119
Study 15280841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 11065206 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 881
Study 11065206 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3-receptor antagonists
Number of subjects: 881
Study 11065206 — intervention group
Group type: COMPARATOR
Intervention: Combination of droperidol and 5-HT3-receptor antagonists
Number of subjects: 881
Study 9302301 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4 mg of zanamivir by intranasal spray plus 10 mg by inhalation
Number of subjects: 417
Study 9302301 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of zanamivir by inhalation
Number of subjects: 417
Study 9302301 — intervention group
Group type: COMPARATOR
Intervention: Placebo by both routes
Number of subjects: 417
Study 9302301 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir groups (both inhaled and intranasal)
Number of subjects: 417
Study 9302301 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (inhaled and intranasal)
Number of subjects: 417
Study 7508055 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (IND, 2.5 mg/day)
Number of subjects: 151
Study 7508055 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ, 25 mg/day)
Number of subjects: 151
Study 7508055 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (NFD, 40 mg/day)
Number of subjects: 151
Study 7508055 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (ENL, 20 mg/day)
Number of subjects: 151
Study 7508055 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (ATL, 100 mg/day)
Number of subjects: 151
Study 2834478 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin, fragmine (5,000 anti‐Xa U/24 h)
Number of subjects: 50
Study 2834478 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin, calciparin (5,000 IU/8 h)
Number of subjects: 50
Study 2834478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (fragmine and calciparin)
Number of subjects: 50
Study 2834478 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin, fragmine
Number of subjects: 50
Study 29249436 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMISE minimal-risk tool
Number of subjects: 1764
Study 29249436 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMISE minimal-risk tool (re-estimated covariate coefficients)
Number of subjects: 1764
Study 27110893 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 24 U in crow's feet lines
Number of subjects: 1362
Study 25401967 — intervention group
Group type: EXPERIMENTAL
Intervention: Equistasi group (wearing active device)
Number of subjects: 40
Study 25401967 — intervention group
Group type: COMPARATOR
Intervention: Inactive device group (control)
Number of subjects: 40
Study 23545929 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 new skin brightener formulations containing SMA‐432
Number of subjects: 68
Study 23545929 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone (HQ)
Number of subjects: 68
Study 20685748 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 6184
Study 20685748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg
Number of subjects: 6184
Study 20685748 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol plus Fluticasone propionate (SFC)
Number of subjects: 6184
Study 20685748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6184
Study 18647093 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous irradiation with polychromatic visible polarized light (540‐780 nm; 68% polarization; power density 3.0 E‐10 W/cm(2)) for 28 consecutive days
Number of subjects: 0
Study 18647093 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 16984739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (1 mg/kg body weight/day)
Number of subjects: 0
Study 16984739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16984739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 0
Study 14559692 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FLAG regimen (n=10): Fludarabine (50 mg/d, VDx5 d) and Ara‐C (200 mg/d, VDx5 or 7 d)
Number of subjects: 16
Study 14559692 — intervention group
Group type: COMPARATOR
Intervention: Classic FLAG regimen (n=6): Fludarabine (50 mg/d, VDx5d), Ara‐C (500 or 1,000 mg/d, VDx5d) and G‐CSF (300 microg/d, x5 d)
Number of subjects: 16
Study 14559692 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FLAG regimen (n=10)
Number of subjects: 16
Study 14559692 — intervention group
Group type: COMPARATOR
Intervention: Classic FLAG regimen (n=6)
Number of subjects: 16
Study 10691817 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin with salivary stimulant pastilles
Number of subjects: 67
Study 10691817 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin alone
Number of subjects: 67
Study 9076201 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 46
Study 9076201 — intervention group
Group type: COMPARATOR
Intervention: Non-patching
Number of subjects: 46
Study 8408860 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted self‐directed learning (ASD)
Number of subjects: 19
Study 8408860 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture methods (TLM)
Number of subjects: 19
Study 2951131 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24
Study 2951131 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 24
Study 31268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit instantaneous wave‐free ratio
Number of subjects: 73
Study 31268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting distal pressure/aortic pressure
Number of subjects: 73
Study 31268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)
Number of subjects: 73
Study 31268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve
Number of subjects: 73
Study 31268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperemic index of microcirculatory resistance
Number of subjects: 73
Study 31268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting microcirculatory resistance
Number of subjects: 73
Study 31268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal pressure from rest to hyperemia
Number of subjects: 73
Study 31268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive reserve ratio
Number of subjects: 73
Study 28104251 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300mg every 4 weeks
Number of subjects: 94
Study 28104251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 24393627 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Health Program (OHP) participation (G1)
Number of subjects: 194
Study 24393627 — intervention group
Group type: COMPARATOR
Intervention: No Oral Health Program participation (G2)
Number of subjects: 194
Study 23078527 — intervention group
Group type: EXPERIMENTAL
Intervention: TACR1 SNPs (rs3771863, rs3755459, rs1106855)
Number of subjects: 326
Study 23078527 — intervention group
Group type: EXPERIMENTAL
Intervention: TACR1 SNP rs3771863
Number of subjects: 326
Study 23078527 — intervention group
Group type: EXPERIMENTAL
Intervention: TACR1 SNPs
Number of subjects: 326
Study 21705063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment of multiple cardiovascular risk factors
Number of subjects: 3057
Study 21705063 — intervention group
Group type: COMPARATOR
Intervention: Routine care of diabetes
Number of subjects: 3057
Study 19317704 — intervention group
Group type: EXPERIMENTAL
Intervention: PAULA the PAIN-METER
Number of subjects: 48
Study 19317704 — intervention group
Group type: COMPARATOR
Intervention: Standard VAS
Number of subjects: 48
Study 16530576 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melphalan and prednisone plus thalidomide (MPT)
Number of subjects: 255
Study 16530576 — intervention group
Group type: COMPARATOR
Intervention: Oral melphalan and prednisone (MP) alone
Number of subjects: 255
Study 16530576 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin prophylaxis
Number of subjects: 255
Study 12767550 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg conjugated equine estrogens (CEE)
Number of subjects: 25
Study 12767550 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens (CEE)
Number of subjects: 25
Study 10696890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent glyceryl trinitrate ointment
Number of subjects: 132
Study 10696890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 10182389 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management (GEM)
Number of subjects: 160
Study 10182389 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (UPC)
Number of subjects: 160
Study 8334330 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ganciclovir/kg 3 times a week (group A)
Number of subjects: 28
Study 8334330 — intervention group
Group type: COMPARATOR
Intervention: 6 mg ganciclovir/kg once daily for 5 days a week (group B)
Number of subjects: 28
Study 2869077 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 27
Study 2869077 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 27
Study 29449292 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Lifestyle Programme (HELP) - 12 one‐to‐one sessions across 6 months
Number of subjects: 174
Study 29449292 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care - single 1‐hour one‐to‐one nurse‐delivered session
Number of subjects: 174